Close

CMV pp65

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cytomegalovirus is a member of the herpes virus group, which includes herpes simplex virus types 1 and 2, varicella zoster virus (which causes chicken pox), and Epstein Barr virus (which causes infectious mononucleosis). These viruses share a characteristic ability to remain dormant within the body over a long period. CMV viral genes are co-ordinately expressed in groups at various times after infection. Early viral proteins are expressed in the nucleus of infected cells within 3 to 24 hours of infection prior to the commencement of viral DNA replication. This is followed by expression of the early intermediate genes, which encode enzymes required for viral DNA replication. After 48 to 72 hours, a number of late viral antigens may be demonstrated in the nuclei and cytoplasm of infected cells. pp65 is a 65kD phosphorylated glycoprotein and is the most abundant of the late antigens.

Associated Disease
  • HCMV infection
  • TCR Vector Products

  • TCR Cell Products

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-L138 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#1), pCDTCR1 CMV TCRCD8-CMV#1 Human PLKMLNIPSINVHHYPSAAERKH HLA-B3501 Lentiviral   Add to Cart   Datasheet
TCR-L139 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#4), pCDTCR1 CMV TCRCD8-CMV#4 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L140 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#8), pCDTCR1 CMV TCRCD8-CMV#8 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L141 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#9), pCDTCR1 CMV TCRCD8-CMV#9 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L142 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#10), pCDTCR1 CMV TCRCD8-CMV#10 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L143 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#11), pCDTCR1 CMV TCRCD8-CMV#11 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L144 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#12), pCDTCR1 CMV TCRCD8-CMV#12 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L145 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#14), pCDTCR1 CMV TCRCD8-CMV#14 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L146 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#15), pCDTCR1 CMV TCRCD8-CMV#15 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L147 Human anti-CMV pp65 T cell receptor (TCRCD8-CMV#16), pCDTCR1 CMV TCRCD8-CMV#16 Human NLVPMVATV HLA-A0201 Lentiviral   Add to Cart   Datasheet
TCR-L148 Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#1), pCDTCR1 CMV TCRCD4-CMV#1 Human PLKMLNIPSINVHHYPSAAERKH HLA-DRB1*0701 Lentiviral   Add to Cart   Datasheet
TCR-L149 Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#3), pCDTCR1 CMV TCRCD4-CMV#3 Human VELRQYDPVAALFFFDIDLLLQR HLA-DRB1*0701 Lentiviral   Add to Cart   Datasheet
TCR-L150 Human anti-CMV pp65 T cell receptor (TCRCD4-CMV#5), pCDTCR1 CMV TCRCD4-CMV#5 Human VELRQYDPVAALFFFDIDLLLQR HLA-DRB1*0701 Lentiviral   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.